Which has grown faster, GSK or MRNA?

Over the past five years, MRNA grew revenue faster — GSK at a 1.38% CAGR versus MRNA at 19.33%.

Does GSK or MRNA pay a bigger dividend?

GSK pays a dividend (3.78% yield), while MRNA has no payments in the available dividend history.

Is GSK or MRNA more profitable?

GSK runs the higher net margin — GSK at 14.52% versus MRNA at -141.43%.

How have GSK and MRNA total returns compared?

Over the past 5 years, GSK delivered 8.21% and MRNA delivered -20.35% annualized total return. Past performance doesn't predict future results.

GSK plc (GSK) vs Moderna, Inc. (MRNA)

A side-by-side comparison of GSK plc and Moderna, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.

GSK

GSK plc

$98.65B

$49.24HealthcareDelayed quote: Sep 25, 2026, 4:00 PM EDT

MRNA

Moderna, Inc.

$78.91B

$198.88HealthcareDelayed quote: Sep 25, 2026, 4:00 PM EDT

Total return — GSK vs MRNA

growth of $100 · dividends reinvested · last 8y

GSK +65.9% (+6.5%/yr)MRNA +674.0% (+29.2%/yr)MRNA compounded faster over this window

GSK MRNA

GSK vs MRNA: by the numbers

•GSK is the larger company ($98.65B vs $78.91B market cap).
•GSK is profitable (14.52% net margin) while MRNA runs a net loss (-141.43%).
•MRNA grew revenue faster over the past five years (19.33% vs 1.38% CAGR).
•GSK pays a dividend (3.78% yield), while MRNA has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	GSK	MRNA
P/E ratio	15.57	N/A
P/S ratio	2.23	35.42
P/B ratio	4.24	11.67
EV / EBITDA	7.97	N/A
FCF yield	9.46%	N/A

Profitability

Metric	GSK	MRNA
Gross margin	72.71%	55.35%
Operating margin	20.72%	-158.13%
Net margin	14.52%	-141.43%
ROE	27.67%	-46.61%
ROIC	13.95%	-39.16%

Dividends

Metric	GSK	MRNA
Dividend yield	3.78%	N/A
Payout ratio	57.45%	N/A

Growth (annualized)

Metric	GSK	MRNA
Revenue CAGR (5Y)	1.38%	19.33%
EPS CAGR (5Y)	-0.71%	N/A
FCF CAGR (5Y)	-2.45%	N/A
Total return CAGR (5Y)	8.21%	-20.35%

Frequently asked

Which has grown faster, GSK or MRNA?: Over the past five years, MRNA grew revenue faster — GSK at a 1.38% CAGR versus MRNA at 19.33%.
Does GSK or MRNA pay a bigger dividend?: GSK pays a dividend (3.78% yield), while MRNA has no payments in the available dividend history.
Is GSK or MRNA more profitable?: GSK runs the higher net margin — GSK at 14.52% versus MRNA at -141.43%.
How have GSK and MRNA total returns compared?: Over the past 5 years, GSK delivered 8.21% and MRNA delivered -20.35% annualized total return. Past performance doesn't predict future results.

Go deeper

Full GSK analysis Full MRNA analysis Interactive comparison tool

Dig into the metrics

GSK P/E ratio GSK dividend yield GSK ROE Moderna ROE GSK operating margin Moderna operating margin GSK revenue growth Moderna revenue growth GSK free cash flow Moderna free cash flow

GSK & Moderna appear in these rankings

Highest Dividend Yield Stocks Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.